Abstract. The metastatic process involves the migration and invasion of cancer cells throughout the body to produce secondary tumors at distant sites. Through of epithelial-mesenchymal transition (EMT), cancer cells employ developmental processes to gain migratory and invasive properties. CD44 is the transmembrane adhesion receptor for Hyaluronan (HA) and plays a central role in the remodeling and degradation of HA that leads to cell migration, as well as to cancer invasion and metastasis. CD44 is highly expressed in primary and metastatic colon cancer but lowly expressed in normal tissues. We evaluated the impact of CD44 on EMT and invasion of colon cancer cells. The functional role of CD44 in EMT was determined by the overexpression or knockdown of CD44. CD44 was overexpressed by transfection with plasmid-RT-PCR product and knockdown of CD44 by small hairpin RNA (shRNA)-mediated depletion of CD44 in SW480 colon cancer cells. Morphological changes were evaluated by confocal laser microscopy in the culture media. The expression of EMT markers (E-cadherin/N-cadherin/vimentin/fibronectin/actin/ MMPs) and CD44/EGFR/PI3K-Akt signaling were evaluated using western blotting. The influence of EMT in tumor biology was assessed with proliferation, migration and invasion assays. EMT changes increased in CD44-overexpressing SW480 cells and decreased in CD44 knockdown cells. CD44 activation induced expression of EGFR and activation of phosphatidylinositol 3' kinase (PI3K)/Akt and expression of glycogen synthase kinase-3 β (GSK-3β). In terms of EMT markers, CD44 downregulated E-cadherin expression, upregulated N-cadherin, α-actin, vimentin, fibronectin and MT1-MMP, and inhibited the formation of the membrane-associated E-cadherin-β-catenin complex, which resulted in cell invasion and migration.
Introduction
Epithelial-mesenchymal transition (EMT), a highly conserved process governing morphogenesis, which occurs during a critical phase of embryonic development in multicellular organisms. In mammals, EMT first occurs at the blastula stage, during formation of the parietal endoderm, which later contributes to the extra embryonic tissues (1, 2) . EMT is reactivated in a variety of diseases, including renal fibrosis, liver cirrhosis, breast cancer, and anterior polar cataracts. EMT comprises a shift in cell phenotype that plays an important role in morphogenetic events spanning embryogenesis important to heart valve formation, as well as in homeostatic mechanisms governing tissue regeneration, inflammation and wound healing. EMT also contributes to disease states, such as fibrosis and cancer. In the latter condition, EMT is thought to contribute to treatment resistance via its antiapoptotic effects (3) . In epithelial cancer, EMT is characterized by a switch in cell membrane cadherins (from E-to N-cadherin), a change from apical-basal to frontback polarity, and acquisition of motility enabled in part by the restructuring of the actin cytoskeleton (4, 5) . During EMT, epithelial cells lose cell polarity by downregulating the expression of cytokeratins and cell-cell adhesion molecules such as E-cadherin (6, 7) . The decrease in epithelial gene expression is accompanied by an increased expression of mesenchymal genes, including vimentin and fibronectin. Following passage through EMT, epithelial cells also acquire mesenchymal morphology in adherent culture, as well as increased motility and invasiveness (8, 9) .
CD44 is the principal transmembrane adhesion receptor for hyaluronan (HA) and plays a central role in the remodeling and degradation of HA that leads to cell migration, as well as to cancer invasion and metastasis (10) (11) (12) (13) . The cytoplasmic tail of CD44 recruits ezrin-radixin-moesin (ERM) proteins that are linked to the actin cytoskeleton and thereby promote cell motility. Expression of CD44 is upregulated not only in cancer cells but also in cells associated with inflammatory diseases, and inflammation-mediated fibrosis in the lung and kidney. As a principal receptor for HA, CD44 participates in the activation of leukocytes and parenchymal cells in areas of inflammation, suggesting a role for CD44 in tissue remodeling and fibrosis (14, 15 and motility of fibroblasts, thereby supporting a role for CD44 in tissue remodeling (16) (17) (18) (19) . In vitro wound assays to compare the migratory properties of primary lung fibroblasts isolated from CD44 wild-type and CD44 deficient mice revealed that CD44 is important both in maintaining the integrity of the actin cytoskeleton and in facilitating an organized, directional migratory response to injury (20) (21) (22) (23) . CD44 also promotes MMP-dependent activation of EGFR, and exogenous EGFR rescues the morphological phenotype and velocity of migration of fibroblasts (24) . CD44 may be critical for the migration of fibroblasts to sites of injury and the local effects of EGFR may depend on the activity of CD44 to control inflammation and initiate the repair process (25) (26) (27) . Metastasis is a complex process involving the spread of malignant tumor cells from a primary tumor site to a secondary organ and colonization of the distant organ. The progression of cancer has been shown to correlate directly with gene changes that regulate a number of steps responsible for metastasis, including EMT (28) (29) (30) (31) . In the process of EMT, cancer cells employ developmental processes to gain migratory and invasive properties. Here we have developed an in vitro model of EMT-associated invasion of colon carcinoma cells and clarified the HA-CD44 interaction. Finally, we aimed to evaluate the impact of CD44 on EMT and invasion of colon cancer cells.
Materials and methods
Cell culture. SW480 cells were obtained from the ATCC cell line bank. They were cultured in DMEM (Lonza) containing 1% penicillin and streptomycin, and 10% heat-inactivated fetal bovine serum. In all experiments, cells were maintained at 37˚C in a humidified 5% CO 2 incubator.
Cell transfection. pcDNA6 vector (Invitrogen, San Diego, CA, USA) containing a GFP sequence and plasmid RT-PCR product (sense: AAGCTTCTCCGGACACCATGGAC, antisense: GTACCATGGTGTAGGTGTTACAC) was used for overexpression of CD44. Short hairpin RNA CD44 (sense: GACAGAAAGCCAAGTGGACTCAACGGAGA: OriGene Technologies, Inc., Rockville, MD, USA) and pGFP-V-RSvector containing a non-effective shRNA cassette against GFP were used for knockdown of CD44 expression. For transfection, approximately 2.0x10 4 SW480 cells were seeded in 6-well plates. When the cells reached 60%-80% confluence, cells were transfected with pcDNA6, pGFP-V-RS shRNA-CD44 and pGFP-V-RS-NC (normal control) by use of Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions and the ratio of the plasmids to the transfection reagent was 1 µg:3 µl. At 48 h post-transfection, 500 µg/ml of puromycin (Sigma, St. Louis, MO, USA) was added to select stable transfected cell lines and individual clones were isolated. The stably-transfected cells were named as follows: SW480-CD44-overexpression (transfected with pcDNA6 vector containing a CD44 plasmid), SW480-S-CD44 (transfected with pGFP-V-RS shRNA-CD44) and SW620-NC (transfected with pGFP-V-RS-vector containing a non-effective shRNA cassette).
Immunofluorescence microscopy. Indirect immunofluorescence microscopy using confocal laser was used for taking pictures of individual cells. In brief, cells on glass coverslips were fixed with 4% paraformaldehyde in phosphate buffered saline (PBS) and permeabilized with 0.1% Triton X-100 and 0.1% Tween-20 (Sigma). Samples were then incubated with primary antibodies for CD44 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), β-catenin (Santa Cruz Biotechnology Inc.), fibronectin (BD Biosciences, Oxford, UK), vimentin (Santa Cruz Biotechnology Inc.), MT1-MMP (Santa Cruz Biotechnology Inc.), E-cadherin (Cell Signaling, Danvers, MA, USA), N-cadherin (Cell Signaling) in PBS with 1% bovine serum albumin (BSA) for 1 h. Negative control cells were incubated with 1% BSA in parallel. Incubation with Alexa 594 and DAPI conjugated secondary antibody followed. Samples were mounted with Vectashield (Vector Laboratories, Burlingame, CA, USA) and examined with a Zeiss LSM 410 confocal laser-scanning immunofluoresence microscope (Olympus, Japan). Cells cultured on glass coverslips were fixed with 4% paraformaldehyde in PBS, the cells on glass were stained with Diff-Quick solution (Sysmex, Kobe, Japan) and checked for morphologic changes in 5 selected fields under a light microscope.
Cell viability and apoptotic assays. SW480 colon cancer and transfected cell lines were cultured in 96-well plates for 24 h. Trypan blue dye exclusion or MTT assay for cell viability and apoptotic assay using Annexin V-APC were performed on the cell lines.
Reverse transcription-polymerase chain reaction. Total RNA was extracted from cultured cells using Trizol reagent (Invitrogen). RNA (1 µg/µl) was used to synthesize cDNA using Superscript First-Strand Synthesis Kit (Promega, Madison, WI, USA) following the manufacturer's protocols. Expression of CD44 mRNA was detected with RT-PCR (Takara, Shiga, Japan) using specific primers (CD44 primer sense and antisense; Table I ).
Cell migration assay. Cells were cultured in a 6-well plate and transfected with CD44-plasmid. After incubation for 48 h, a scratch wound was made by creating a linear cell-free region using a 200 µl pipette tip resulting in a uniform gap. The medium was changed to 5% FBS/DMEM media. The progress of cell migration into the scratch was photographed at 0, 24, and 48 h using an inverted microscope. The distance between gaps was normalized to 1 cm after capture of 6 random sites.
Cell invasion assay. Transwell filters (8.0 µm pores) were coated with matrigel/DMEM overnight and dried out at room temperature. Cells transfected with CD44-plasmid were seeded at 2x10 5 cells in 120 µl 0.2% BSA medium in the upper chamber. Subsequently, 400 µl 0.2% BSA medium containing 20 µg/ml human plasma fibronectin (Calbiochem, La Jolla, CA, USA), a chemotacic factor, were loaded into the lower chamber. After incubation for 24 h, invaded cells on the bottom surface of the transwell were stained with Diff-Quick solution (Sysmex, Kobe, Japan) and counted in 5 selected fields under a light microscope. Data were expressed as the mean standard error (SE) of the number of cells/field in 3 individual experiments.
Western blotting. The cells were washed twice with cold PBS and lysed with RIPA buffer (1 M Tris-HCl, 150 mM NaCl, 1% Triton X-100, 2 mM EDTA) with 1 mM PMSF, Halt phosphatase inhibitor, and Halt protease inhibitor cocktail (Thermo, Rockford, IL, USA) for 15 min on ice. The resolved proteins underwent centrifugation at 15,000 g for 20 min at 4˚C. The protein quantification of supernatants was determined using BCA protein assay (Thermo) and all samples were separated by 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and the separated proteins were transferred electrophoretically from the gel to the surface of PVDF membrane (Millipore, Billerica, MA, USA). The analysis used primary antibodies as described by the manufacturers of the antibodies; monoclonal anti-CD44 (Santa Cruz Biotechnology Inc.), EGFR (Cell Signaling), PDK1 (Cell Signaling), PI3k (Cell Signaling), p-AKT (Cell Signaling), GSK3β (Cell Signaling), GAPDH (Santa Cruz Biotechnology Inc.), β-catenin (BD Biosciences), E-cadherin (Cell Signaling), N-cadherin (Cell Signaling), Vimentin (Santa Cruz Biotechnology Inc.), Fibronectin (BD Biosciences), α-actin (Santa Cruz Biotechnology Inc.), Garma-tuburin (Santa Cruz Biotechnology Inc.), MT1-MMP (Santa Cruz Biotechnology Inc.). After the final rinsing with TBST, the membrane was incubated with secondary HRP-linked anti-rabbit IgG or anti-mouse IgG for 1 h. After washing, the immunoblots were visualized using chemiluminescence (ECL) HRP substrate (Millipore) and analyzed with an image analyzer (Ras-4000, Fujifilm, Tokyo, Japan)
Results

CD44 expression. CD44 expression was evaluated by RT-PCR
and western blotting considering overexpression by plasmid RT-PCR product of CD44 and knockdown by shRNA CD44. As shown in Fig. 1, CD44 overexpressed cells showed increased expression of CD44 and CD44 knockdown cells showed decreased expression of CD44 compared to parental cells.
Morphologic changes.
The round epithelial feature changed into a long tubular shape, which was characteristic of mesenchymal features in the CD44 overexpressed cells (Fig. 2) . This is defined as epithelial mesenchymal transition (EMT). This phenomenon is prominent in CD44 overexpressed cells but no evidence of morphologic changes in parental and CD44 knockdown SW480 cells is seen.
Cell migration assay.
As determined by the wound healing assay, CD44 overexpressed cells showed significantly increased cell migration compared to SW480 vector by 156% at Day 2. By contrast, CD44 knockdown cells showed a marked decreased migratory capacity compared to vector by 17% at Day 2 (Fig. 3) .
Cell invasion assay.
As determined by Matrigel invasion assay throughout transwell, CD44 overexpressed cells showed increased cell invasion compared to vector by 252%, whereas shRNA CD44 decreased cell invasion by 71.05% in 24 h after cell plating (Fig. 4) β-catenin expression. CD44 overexpressed cells showed upregulated β-catenin expression in the nucleus and a marked decrease of β-catenin in CD44 knockdown cells by western blot analysis and immunofluorescence microscopy using Alexa Fluor 594 and DAPI (Fig. 5) .
Activation of AKT pathways. As a mediator of EMT inducer, CD44 triggered the EGFR-Akt signaling pathway, CD44 increased EGFR expression and expression of downstream molecules of EGFR: PI3K, AKT, GSK3β. Western blot analysis showed increased expression of EGFR, PI3K, AKT, GSK3β in CD44 overexpressed cells and decreased expression in CD44 knockdown cells (Fig. 6) .
EMT markers. To evaluate the direct correlation between CD44 and EMT, we examined the expressions of E-cadherin, N-cadherin, vimentin, fibronectin, α-actin, MT1-MMP. CD44 overexpression of colon cancer cells inhibited E-cadherin expression, whereas it induced the expression of N-cadherin, vimentin, fibronectin, α-actin, MT1-MMP. By contrast, knockdown of CD44 increased E-cadherin expression and downregulated N-cadherin, vimentin, fibronectin, α-actin, and MT1-MMP in the western blotting (Fig. 7) and confocal immunofluorescence images (Fig. 8) .
Discussion
The hallmarks of malignant transformation are the capabilities of invasion and metastasis. In order for these processes to proceed, tumor cells must be able to detach from the primary tumor, migrate, gain access to blood or lymphatic vessels and disseminate in the body (32) . It is assumed that a dedifferentiation of the tumor cells in the invasive area characterized by a loss of an epithelial layer and the gain of a mesenchyme-like phenotype enables invasive and metastatic growth of differentiated colorectal cancers. This process is known as an epithelial-mesenchymal transition (EMT). EMT is very significant for malignant colorectal cancer progression (33) . Several pathways involved in the developmental control of EMT are taken over during tumor formation by activation of oncogenic signaling and disruption of tumor suppressor networks. In this E-cadherin. β-catenin has a dual role in EMT; it enhances cellcell adhesion when bound to cadherin complexes in adherens junctions and also functions as a transcriptional coactivator upon entry into the nucleus (35) . Nuclear import of β-catenin is another important player in EMT (36, 37) . Nuclear β-catenin induces a gene expression pattern favoring tumor invasion and proceeds with transition to the mesenchymal phenotype of epithelial tumor cells (38) .
Cells that had undergone EMT exhibited CD44 high expression, suggesting that the EMT may confer malignant properties on tumor cells (39) . Upregulation of CD44 and downregulation of CD44 seem to be involved in the EMT process and the acquisition of invasive and metastatic potential (40) (41) (42) (43) . In this study, treatment with shRNA-CD44 induced CD44 shedding from the cell surface and significantly decreased cell migration and invasion in SW480 cells. This is assumed to be CD44 repression in colorectal cancer cells induced the reconstitution of an epithelial phenotype and reduced the migratory and invasive properties of cancer cells in SW480 cells.
Furthermore, CD44 expression is regulated by the β-catenin/Tcf-4 signaling pathway, especially in the colorectal cancer precursor lesions, suggesting a role for CD44 in intestinal tumorigenesis. Consequently, nuclear β-catenin and upregulation of CD44 may be a potential mechanism for colon cancer metastasis (44, 45) . The requirement of CD44 for EGFR/Akt induced EMT was verified in several reports (46) (47) (48) . We showed that overexpression of CD44 in SW480 colon cancer cells strongly related to downregulation of E-cadherin, upregulation of N-cadherin and α-actin, and vimentin, fibronectin, MT1-MMP, suggesting that CD44 function was a prerequisite for EGFR/Akt -induced responses associated with EMT.
In conclusion, CD44 in SW480 colon cancer cells strongly induced EMT which occurred due to the downregulation of E-cadherin, upregulation of N-cadherin, α-actin, vimentin, fibronectin, and MT1-MMT. CD44 also led to EGFR/ Akt-induced signaling associated with EMT. CD44 is a potent EMT inducer and may be an important mediator for invasion and/or metastasis of colon cancer.
